BioGaia AB (BIOG B):企業の財務・戦略的SWOT分析

◆英語タイトル:BioGaia AB (BIOG B) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH81785FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年2月
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

BioGaia AB (BIOG B) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

BioGaia AB (BioGaia) is a biopharmaceutical company, which develops, markets and sells probiotic products. The company sells its probiotic food supplements and oral health products in various dosage forms including drops, lozenges, tablets, chewable tablets, oral rehydration salts (ORS), straws and infant formulas. The company’s major product areas include baby and child gut health, adult gut health, probiotic gastrointestinal health, oral health and bone health. BioGaia’s products are based on various strains of Lactobacillus reuteri, its patented lactic acid bacterium. Its products improve the digestive and oral health of children and adults and controls digestive problems such as colic, regurgitation, diarrhoea and constipation. The company’ sells its products through distributors in the Americas, Europe and Asia-Pacific. BioGaia is headquartered in Stockholm, Sweden.

BioGaia AB Key Recent Developments

Feb 12,2021: MetaboGen has reached a new crucial milestone in its development of novel probiotic products
Feb 04,2021: BioGaia announces year-end report 2020
Oct 23,2020: BioGaia: Interim management statement January – September 2020
Oct 12,2020: BioGaia: Reduced sales due to covid-19
Aug 13,2020: BioGaia: Interim Report January – June 2020

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
BioGaia AB – Key Facts
BioGaia AB – Key Employees
BioGaia AB – Key Employee Biographies
BioGaia AB – Major Products and Services
BioGaia AB – History
BioGaia AB – Company Statement
BioGaia AB – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
BioGaia AB – Business Description
Business Segment: Adult Health
Overview
Performance
Business Segment: Other
Overview
Performance
Business Segment: Paediatrics
Overview
Performance
Geographical Segment: Americas
Performance
Geographical Segment: Asia Pacific
Performance
Geographical Segment: EMEA
Performance
R&D Overview
BioGaia AB – Corporate Strategy
BioGaia AB – SWOT Analysis
SWOT Analysis – Overview
BioGaia AB – Strengths
BioGaia AB – Weaknesses
BioGaia AB – Opportunities
BioGaia AB – Threats
BioGaia AB – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
BioGaia AB, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 12, 2021: MetaboGen has reached a new crucial milestone in its development of novel probiotic products
Feb 04, 2021: BioGaia announces year-end report 2020
Oct 23, 2020: BioGaia: Interim management statement January – September 2020
Oct 12, 2020: BioGaia: Reduced sales due to covid-19
Aug 13, 2020: BioGaia: Interim Report January – June 2020
May 07, 2020: BioGaia Interim Management Statement 1 January – 31 March 2020
Mar 30, 2020: BioGaia update concerning COVID-19 pandemic
Feb 06, 2020: BioGaia – Year-end report 2019
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
BioGaia AB, Key Facts
BioGaia AB, Key Employees
BioGaia AB, Key Employee Biographies
BioGaia AB, Major Products and Services
BioGaia AB, History
BioGaia AB, Other Locations
BioGaia AB, Subsidiaries
BioGaia AB, Key Competitors
BioGaia AB, Ratios based on current share price
BioGaia AB, Annual Ratios
BioGaia AB, Annual Ratios (Cont...1)
BioGaia AB, Annual Ratios (Cont...2)
BioGaia AB, Interim Ratios
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
BioGaia AB, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[BioGaia AB (BIOG B):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cox & Kings Limited
    Cox & Kings Limited - Strategy, SWOT and Corporate Finance Report Summary Cox & Kings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Promedior Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Promedior Inc (Promedior) is a clinical-stage biotechnology company that develops medicines for the treatment of fibrotic disorders. The company’s pipeline products include PRM-151 and PRM-167. PRM-151 is used in the treatment of rare systemic fibrotic diseases such as myelofibrosis and idio …
  • Stantec Inc:企業のM&A・事業提携・投資動向
    Stantec Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Stantec Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • LifeAssays AB (LIFE B)-医療機器分野:企業M&A・提携分析
    Summary LifeAssays AB (LifeAssays) is a medical device company that develops, manufactures and markets in-vitro diagnostic and veterinary care products. The company provides point-of-care diagnostic testing systems. Its product portfolio includes lifeassays human system and lifeassays veterinary sys …
  • ConMed Corp (CNMD):企業の財務・戦略的SWOT分析
    ConMed Corp (CNMD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Pharmadax Inc (4191):製薬・医療:M&Aディール及び事業提携情報
    Summary Pharmadax Inc (Pharmadax) is a drug development and generic specialty pharmaceutical company. The company develops modified release generics in various therapeutic segments. It offers products such as glyburide, quetiapine fumarate ER and metoprolol succinate ER. Pharmadax provides in the pr …
  • Oracle Corporation Japan (4716):企業の財務・戦略的SWOT分析
    Summary Oracle Corporation Japan (Oracle Corp) is an information technology company that offers software and hardware services. The company offers integrated cloud applications and platform services. It develops software and hardware products, solutions, consulting, support services, education busin …
  • Herantis Pharma Plc (HRTIS):医療機器:M&Aディール及び事業提携情報
    Summary Herantis Pharma Plc (Herantis Pharma) is a drug development company that offers regenerative medicine for neurodegenerative diseases. The company's pipeline products include CDNF for amyotrophic lateral sclerosis, CDNF for Parkinson’s disease and lymfactin for secondary lymphedema. Its lymfa …
  • BYD Company Limited:企業の戦略・SWOT・財務分析
    BYD Company Limited - Strategy, SWOT and Corporate Finance Report Summary BYD Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • CRH Plc (CRH):企業の財務・戦略的SWOT分析
    CRH Plc (CRH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Navidea Biopharmaceuticals Inc (NAVB):医療機器:M&Aディール及び事業提携情報
    Summary Navidea Biopharmaceuticals Inc (Navidea) is a biopharmaceutical company that develops precision immunodiagnostic agents and immunotherapeutics.. The company is focused on developing multiple precision-targeted products based on its Manocept platform to improve patient care. Its pipeline prod …
  • Standard Alliance Insurance Plc:企業の戦略・SWOT・財務情報
    Standard Alliance Insurance Plc - Strategy, SWOT and Corporate Finance Report Summary Standard Alliance Insurance Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • University of Southern California-製薬・医療分野:企業M&A・提携分析
    Summary University of Southern California (USC) is a medical education and research institution that provides educational courses in the field of arts and sciences, accounting, architecture, art and design, arts and tech, business, cinematic arts, communication, journalism and dance. The institute a …
  • Nippon Steel & Sumikin Chemical Co Ltd:企業の戦略的SWOT分析
    Nippon Steel & Sumikin Chemical Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and ma …
  • AECOM (ACM):企業の財務・戦略的SWOT分析
    AECOM (ACM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the poten …
  • Cleveland BioLabs, Inc.:企業のM&A・事業提携・投資動向
    Cleveland BioLabs, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Cleveland BioLabs, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • Enel Russia (ENRU):電力:M&Aディール及び事業提携情報
    Summary Enel Russia, a subsidiary of Enel Investment Holding BV, is an energy utility. It produces electricity and thermal energy. The company generates electricity using coal, gas and fuel oil sources. Enel Russia owns and operates Konakovskaya GRES, Nevinnomysskaya GRES, Reftinskaya GRES and Sredn …
  • Cordy Oilfield Services Inc (CKK):石油・ガス:M&Aディール及び事業提携情報
    Summary Cordy Oilfield Services Inc (Cordy) is an oilfield and construction service provider. The company offers construction and environmental services. Its construction services include underground utilities installation and maintenance, pipeline insulation and reclamation, pump jack maintenance, …
  • Blueprint Medicines Corp (BPMC)-医療機器分野:企業M&A・提携分析
    Summary Blueprint Medicines Corp (Blueprint) is a biotechnology company that develops drugs for the treatment of cancers. The company discovers selective kinase inhibitors for genomically defined cancer subsets. Its pipeline products include BLU-285, for treatment resistant gastrointestinal stromal …
  • Sasol Ltd (SOL)-石油・ガス分野:企業M&A・提携分析
    Summary Sasol Ltd (Sasol) is an integrated energy and chemical company. It develops and commercializes technologies; and builds and operates facilities to produce a range of products, including liquid fuels, chemicals, and low-carbon electricity. The company’s product offerings include olefins and s …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆